Business Wire

EXCLUSIVE-NETWORKS

Share
Exclusive Networks Appoints Jesper Trolle as CEO

Exclusive Networks (‘Exclusive’) today announced the appointment of Jesper Trolle as CEO with immediate effect. Trolle joins Exclusive from ECS Arrow Electronics, where he is currently President of the Americas, and will be responsible for driving the next phase of growth at the company and upscaling the business. Trolle takes over from Olivier Breittmayer who becomes a non-executive Board member of Exclusive. The move is part of a planned succession strategy and Trolle will work alongside Breittmayer for the next three months to ensure a smooth transition.

Vastly experienced and recognised as an entrepreneurial business leader within the IT industry, Trolle has spent over 28 years working in the sector, initially within the reseller community, before moving into distribution. In 2001 he founded Next Denmark A/S which was acquired by DNS Denmark, which in turn was acquired by Arrow in 2005. Since then, Jesper has held a number of diverse positions in multiple locations within Arrow, seeing rapid success and progression, including stints in Germany running central and eastern Europe, and Paris, running north-west Europe. He took up the role as Arrow’s President Americas in 2017, based out of Denver, Colorado, where he has successfully grown a double-digit $bn business.

Speaking about the appointment, Breittmayer said, “Jesper was the standout choice following an intensive search and selection process these last six months or so. His cultural and international experience, obvious entrepreneurial DNA, knowledge of upscaling global businesses at pace and empathy with value-based distribution is impressive and refreshing. It is with confidence and a smile that we are getting such a capable person to take over the helm of the business we’ve grown by some 2,000% over the last 17 years.”

Talking of his appointment Trolle added, “Opportunities like this do not come around that often, but in distribution, Exclusive is at the top of the list if they do. I’m delighted to be joining such a successful company with a strong reputation for innovation and exceptional growth. Exclusive is renowned for its disruptive approach and relentless focus on value creation for its partners. When given the opportunity to become a part of the Exclusive family and next phase of its journey, it was an easy and fast decision to make.

“Olivier’s vision of creating the only specialist distributor on a global scale, focused on high performance cybersecurity infrastructure, was imaginative and disruptive – and that vision has become reality. Exclusive continues to buck market trends, growing at pace organically, expanding geographically and still disrupting. The only thing that hasn’t changed or been diluted is the obsession with value, services and specialism. This scale and specialist approach has never before been achieved. My job is clear: turn the global presence into a cybersecurity infrastructure powerhouse, at scale and speed, and it is a challenge I relish, feel qualified to do and very much look forward to,” concluded Trolle.

Michail Zekkos, Partner at Permira, and a member of Exclusive’s Board of Directors, commented, “Olivier is a pioneer and a true inspiration in modern day value-based distribution. It was a hard task to find his natural replacement, but in Jesper we feel we have done just that. He’s exceptionally talented and culturally very aligned to L’Esprit Exclusive. Olivier’s vision of building the Exclusive ‘Network’ of value-based distribution businesses, globally guided but locally delivered, was unique.

“The business has consistently outperformed market growth rates; expanded at breathtaking speed and delivered financial results that are exceptional for the sector. This is a great platform from which Jesper can continue the adventure and scale-out the business, and with his vision, multicultural background and experience of growth at scale we feel confident he is more than able to meet the challenge.

“Myself and the rest of the Exclusive family thank Olivier wholeheartedly for his indelible impact on the company, and welcome him onto the Board of Directors.”

Breittmayer added finally, “It’s not goodbye, it’s à plus tard.”

-ends-

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye